Does the media refer more to ANVS or CORT?

In the previous week, Corcept Therapeutics had 27 more articles in the media than Annovis Bio. MarketBeat recorded 31 mentions for Corcept Therapeutics and 4 mentions for Annovis Bio. Corcept Therapeutics' average media sentiment score of 0.77 beat Annovis Bio's score of 0.62 indicating that Corcept Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor ONC or CORT?

In the previous week, Corcept Therapeutics had 28 more articles in the media than BeOne Medicines. MarketBeat recorded 31 mentions for Corcept Therapeutics and 3 mentions for BeOne Medicines. Corcept Therapeutics' average media sentiment score of 0.77 beat BeOne Medicines' score of 0.63 indicating that Corcept Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor RPRX or CORT?

In the previous week, Corcept Therapeutics had 23 more articles in the media than Royalty Pharma. MarketBeat recorded 31 mentions for Corcept Therapeutics and 8 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.89 beat Corcept Therapeutics' score of 0.77 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has stronger valuation and earnings, ZTS or CORT?

Zoetis has higher revenue and earnings than Corcept Therapeutics. Zoetis is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zoetis $9.47B 3.39 $2.67B $6.07 12.80 Corcept Therapeutics $830.81M 15.91 $99.65M $0.42 291.07

Does the media favor ZTS or CORT?

In the previous week, Corcept Therapeutics had 11 more articles in the media than Zoetis. MarketBeat recorded 31 mentions for Corcept Therapeutics and 20 mentions for Zoetis. Zoetis' average media sentiment score of 1.20 beat Corcept Therapeutics' score of 0.77 indicating that Zoetis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 14 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Corcept Therapeutics (CORT) Competitors

$122.25 +1.20 (+0.99%)

As of 08/21/2026 04:00 PM Eastern

Compare

CORT vs. ANVS, TEVA, ONC, RPRX, and ZTS

Should you buy Corcept Therapeutics stock or one of its competitors? Corcept Therapeutics's main competitors and comparable companies include Annovis Bio (ANVS), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), Royalty Pharma (RPRX), and Zoetis (ZTS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Corcept Therapeutics compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Corcept Therapeutics has a net margin of 6.52% compared to Annovis Bio's net margin of 0.00%. Corcept Therapeutics' return on equity of 8.26% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-685.98%	-258.77%
Corcept Therapeutics	6.52%	8.26%	6.45%

In the previous week, Corcept Therapeutics had 27 more articles in the media than Annovis Bio. MarketBeat recorded 31 mentions for Corcept Therapeutics and 4 mentions for Annovis Bio. Corcept Therapeutics' average media sentiment score of 0.77 beat Annovis Bio's score of 0.62 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	11 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 20.8% of Annovis Bio shares are held by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Corcept Therapeutics has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A
Corcept Therapeutics	$830.81M	15.91	$99.65M	$0.42	291.07

Annovis Bio has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market.

Annovis Bio currently has a consensus price target of $11.67, indicating a potential upside of 544.57%. Corcept Therapeutics has a consensus price target of $138.17, indicating a potential upside of 13.02%. Given Annovis Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Annovis Bio is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Corcept Therapeutics beats Annovis Bio on 11 of the 16 factors compared between the two stocks.

How does Corcept Therapeutics compare to Teva Pharmaceutical Industries?

Corcept Therapeutics (NASDAQ:CORT) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

Corcept Therapeutics presently has a consensus price target of $138.17, suggesting a potential upside of 13.02%. Teva Pharmaceutical Industries has a consensus price target of $42.22, suggesting a potential upside of 12.98%. Given Corcept Therapeutics' higher possible upside, equities research analysts clearly believe Corcept Therapeutics is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Teva Pharmaceutical Industries has higher revenue and earnings than Corcept Therapeutics. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$830.81M	15.91	$99.65M	$0.42	291.07
Teva Pharmaceutical Industries	$17.31B	2.52	$1.41B	$0.60	62.28

93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. 20.7% of Corcept Therapeutics shares are held by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Corcept Therapeutics has a net margin of 6.52% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.52%	8.26%	6.45%
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%

Corcept Therapeutics has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

In the previous week, Corcept Therapeutics had 22 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 31 mentions for Corcept Therapeutics and 9 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.80 beat Corcept Therapeutics' score of 0.77 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	11 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Corcept Therapeutics and Teva Pharmaceutical Industries tied by winning 8 of the 16 factors compared between the two stocks.

How does Corcept Therapeutics compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Corcept Therapeutics (NASDAQ:CORT) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

BeOne Medicines has higher revenue and earnings than Corcept Therapeutics. BeOne Medicines is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	7.69	$286.93M	$5.68	65.93
Corcept Therapeutics	$830.81M	15.91	$99.65M	$0.42	291.07

BeOne Medicines has a net margin of 10.70% compared to Corcept Therapeutics' net margin of 6.52%. BeOne Medicines' return on equity of 14.23% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	10.70%	14.23%	7.82%
Corcept Therapeutics	6.52%	8.26%	6.45%

BeOne Medicines presently has a consensus target price of $402.14, indicating a potential upside of 7.39%. Corcept Therapeutics has a consensus target price of $138.17, indicating a potential upside of 13.02%. Given Corcept Therapeutics' higher possible upside, analysts clearly believe Corcept Therapeutics is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Corcept Therapeutics had 28 more articles in the media than BeOne Medicines. MarketBeat recorded 31 mentions for Corcept Therapeutics and 3 mentions for BeOne Medicines. Corcept Therapeutics' average media sentiment score of 0.77 beat BeOne Medicines' score of 0.63 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	11 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

BeOne Medicines has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market.

Summary

BeOne Medicines beats Corcept Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Corcept Therapeutics compare to Royalty Pharma?

Royalty Pharma (NASDAQ:RPRX) and Corcept Therapeutics (NASDAQ:CORT) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

Royalty Pharma has a net margin of 32.14% compared to Corcept Therapeutics' net margin of 6.52%. Royalty Pharma's return on equity of 30.01% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	32.14%	30.01%	14.91%
Corcept Therapeutics	6.52%	8.26%	6.45%

54.4% of Royalty Pharma shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 18.8% of Royalty Pharma shares are owned by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Royalty Pharma has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market.

Royalty Pharma has higher revenue and earnings than Corcept Therapeutics. Royalty Pharma is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.38B	14.82	$770.95M	$1.45	42.28
Corcept Therapeutics	$830.81M	15.91	$99.65M	$0.42	291.07

In the previous week, Corcept Therapeutics had 23 more articles in the media than Royalty Pharma. MarketBeat recorded 31 mentions for Corcept Therapeutics and 8 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.89 beat Corcept Therapeutics' score of 0.77 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	11 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Royalty Pharma currently has a consensus price target of $60.86, indicating a potential downside of 0.74%. Corcept Therapeutics has a consensus price target of $138.17, indicating a potential upside of 13.02%. Given Corcept Therapeutics' higher probable upside, analysts plainly believe Corcept Therapeutics is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Royalty Pharma beats Corcept Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Corcept Therapeutics compare to Zoetis?

Zoetis (NYSE:ZTS) and Corcept Therapeutics (NASDAQ:CORT) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

Zoetis presently has a consensus target price of $109.23, indicating a potential upside of 40.54%. Corcept Therapeutics has a consensus target price of $138.17, indicating a potential upside of 13.02%. Given Zoetis' higher probable upside, equities analysts plainly believe Zoetis is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Zoetis has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market.

92.8% of Zoetis shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 0.2% of Zoetis shares are owned by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Zoetis has higher revenue and earnings than Corcept Therapeutics. Zoetis is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.47B	3.39	$2.67B	$6.07	12.80
Corcept Therapeutics	$830.81M	15.91	$99.65M	$0.42	291.07

Zoetis has a net margin of 27.49% compared to Corcept Therapeutics' net margin of 6.52%. Zoetis' return on equity of 74.89% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.49%	74.89%	18.59%
Corcept Therapeutics	6.52%	8.26%	6.45%

In the previous week, Corcept Therapeutics had 11 more articles in the media than Zoetis. MarketBeat recorded 31 mentions for Corcept Therapeutics and 20 mentions for Zoetis. Zoetis' average media sentiment score of 1.20 beat Corcept Therapeutics' score of 0.77 indicating that Zoetis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	14 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	11 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Zoetis beats Corcept Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Corcept Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CORT vs. The Competition

Export

Metric	Corcept Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.21B	$12.54B	$7.37B	$12.85B
Dividend Yield	N/A	2.61%	2.53%	11.08%
P/E Ratio	291.08	789.80	272.60	24.24
Price / Sales	15.91	764.50	618.96	99.78
Price / Cash	135.42	96.77	78.62	53.99
Price / Book	18.72	11.89	13.05	6.20
Net Income	$99.65M	$2.81B	$3.47B	$348.59M
7 Day Performance	6.80%	1.77%	2.09%	0.08%
1 Month Performance	26.47%	3.85%	6.64%	3.88%
1 Year Performance	73.82%	6.56%	25.02%	16.98%

Corcept Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CORT Corcept Therapeutics	3.4681 of 5 stars	$122.25 +1.0%	$138.17 +13.0%	+73.8%	$13.21B	$830.81M	291.08	300	Trending News Analyst Forecast Insider Trade Analyst Revision
ANVS Annovis Bio	3.163 of 5 stars	$1.81 -4.2%	$11.67 +544.6%	-24.0%	$65.48M	N/A	N/A	3	News Coverage Earnings Report Analyst Forecast
TEVA Teva Pharmaceutical Industries	3.602 of 5 stars	$36.84 +1.0%	$42.22 +14.6%	+102.4%	$42.51B	$17.26B	61.40	33,950	Analyst Upgrade
ONC BeOne Medicines	3.7585 of 5 stars	$359.05 -0.1%	$402.14 +12.0%	+19.4%	$39.42B	$5.34B	63.21	12,000
RPRX Royalty Pharma	4.3422 of 5 stars	$59.22 +2.5%	$60.86 +2.8%	+68.8%	$33.28B	$2.38B	40.84	80	Analyst Upgrade Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CORT) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Corcept Therapeutics (CORT) Competitors

CORT vs. ANVS, TEVA, ONC, RPRX, and ZTS

How does Corcept Therapeutics compare to Annovis Bio?

Summary

How does Corcept Therapeutics compare to Teva Pharmaceutical Industries?

Summary

How does Corcept Therapeutics compare to BeOne Medicines?

Summary

How does Corcept Therapeutics compare to Royalty Pharma?

Summary

How does Corcept Therapeutics compare to Zoetis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CORT vs. The Competition

Corcept Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Corcept Therapeutics (CORT) Competitors

CORT vs. ANVS, TEVA, ONC, RPRX, and ZTS

How does Corcept Therapeutics compare to Annovis Bio?

Is ANVS or CORT more profitable?

Does the media refer more to ANVS or CORT?

Do institutionals and insiders have more ownership in ANVS or CORT?

Which has stronger earnings and valuation, ANVS or CORT?

Which has more volatility and risk, ANVS or CORT?

Do analysts recommend ANVS or CORT?

Summary

How does Corcept Therapeutics compare to Teva Pharmaceutical Industries?

Do analysts recommend CORT or TEVA?

Which has stronger earnings and valuation, CORT or TEVA?

Do institutionals & insiders believe in CORT or TEVA?

Is CORT or TEVA more profitable?

Which has more volatility & risk, CORT or TEVA?

Does the media prefer CORT or TEVA?

Summary

How does Corcept Therapeutics compare to BeOne Medicines?

Which has better valuation and earnings, ONC or CORT?

Is ONC or CORT more profitable?

Do analysts recommend ONC or CORT?

Do institutionals and insiders believe in ONC or CORT?

Does the media favor ONC or CORT?

Which has more risk and volatility, ONC or CORT?

Summary

How does Corcept Therapeutics compare to Royalty Pharma?

Is RPRX or CORT more profitable?

Do insiders and institutionals believe in RPRX or CORT?

Which has more risk & volatility, RPRX or CORT?

Which has higher earnings & valuation, RPRX or CORT?

Does the media favor RPRX or CORT?

Do analysts recommend RPRX or CORT?

Summary

How does Corcept Therapeutics compare to Zoetis?

Do analysts rate ZTS or CORT?

Which has more volatility & risk, ZTS or CORT?

Do institutionals & insiders have more ownership in ZTS or CORT?

Which has stronger valuation and earnings, ZTS or CORT?

Is ZTS or CORT more profitable?

Does the media favor ZTS or CORT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CORT vs. The Competition

Corcept Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools